21.5.2024 08:08:49 CEST | Demant A/S |
Investor Nyheder
Investor News 21. maj 2024
Afsluttet frasalg af vores cochlear-implantatforretning
Demant meddeler i dag, at alle regulatoriske godkendelser og sædvanlige vilkår vedrørende frasalget af vores cochlear-implantatforretning til Cochlear er blevet opfyldt, og at den foreslåede transaktion er afsluttet med virkning fra den 21. maj 2024. Dette er i overensstemmelse med forventningerne, og i overgangsperioden vil vi arbejde tæt sammen med Cochlear for at sikre en gnidningsfri og ordentlig overgang, således at Cochlear kan fortsætte med at servicere de eksisterende cochlear-implantatpatienter.
Efter afslutningen af frasalget forventer vi fortsat et resultat efter skat fra Hearing Implants på omkring DKK 0 mio. i 2024. Vores forretning for benforankrede høresystemer (BAHS) forbliver en del af koncernen, mens en evaluering af vore strategiske muligheder pågår.
Yderligere information:
Søren Nielsen, koncernchef & adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, Manager of External Communications
Kontakter
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
240521 Afsluttet frasalg af cochlear-implantatforretning.pdf
21.5.2024 08:08:49 CEST | Demant A/S |
Investor News
Investor News 21 May 2024
Closing of the divestment of our cochlear implants business
Today, Demant announces that all regulatory approvals and customary closing conditions regarding the divestment of our cochlear implants business to Cochlear have been fulfilled and that the proposed transaction has closed effective 21 May 2024. This is in line with expectations, and in the transition period, we will work closely together with Cochlear to ensure a smooth and proper transition so they can continue to service the existing cochlear implants patients.
Following the closing of the divestment, we still expect profit after tax related to Hearing Implants to be around DKK 0 million for 2024. Our bone anchored hearing systems business (BAHS) remains with the Group for now, pending a review of strategic options.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, Manager of External Communications
Contacts
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
240521 Closing of divestment of cochlear implants business.pdf
